Algeta News

Algeta ASA : New data and analyses from clinical trials of Xofigo® (radium-223 dichloride) to be presented at ASCO

16 May 2013

Algeta announces that Xofigo® (radium-223 dichloride) has been approved by the US FDA

15 May 2013

Algeta results for the first quarter 2013

15 May 2013

Algeta ASA : Changes in Algeta's Financial Calendar 2013

15 May 2013

Algeta to Participate in Upcoming Investor Conferences

14 May 2013

Algeta schedules first quarter 2013 results presentation, webcast and conference call

07 May 2013

Algeta exercises option and signs exclusive license agreement with Lumiphore, Inc. for novel technology for development of Targeted Thorium Conjugates (TTCs)

02 May 2013

Algeta to Participate in Upcoming Investor Conference

17 April 2013

Algeta ASA : Hilde Furberg and Paolo Pucci elected as new members of Algeta's Board of Directors

12 April 2013

Algeta ASA : Annual General Meeting held in Algeta ASA

11 April 2013

Algeta ASA : Proposal from the Nomination Committee to the Annual General Meeting on 11 April 2013

05 April 2013

Algeta - Notice of Annual General Meeting 2013

19 March 2013

Algeta results for the fourth quarter and full year 2012

28 February 2013

Algeta to Participate in Upcoming Investor Conferences

20 February 2013

Algeta schedules fourth quarter and full year 2012 results presentation, webcast and conference call

18 February 2013

Algeta ASA : Further sub-analyses of ALSYMPCA phase III study presented at 2013 Genitourinary Cancers Symposium

15 February 2013

Algeta ASA : US FDA Grants Priority Review to the New Drug Application for Radium-223 Dichloride for Castration-Resistant Prostate Cancer with Bone Metastases

13 February 2013

Algeta initiates new oncology research program to evaluate the potential of a Targeted Thorium Conjugate (TTC) based on Immunomedics' anti-CD22 monoclonal antibody

28 January 2013

US Nuclear Regulatory Commission issues a licensing decision under 10 CFR Part 35 Subpart E for radium-223 dichloride

14 January 2013

Algeta's partner Bayer submits New Drug Application to US FDA for Radium-223 Dichloride for the Treatment of Castration-Resistant Prostate Cancer with Bone Metastases

14 December 2012

Algeta's partner Bayer submits Radium-223 Dichloride for EU Marketing Authorisation for the Treatment of Castration-Resistant Prostate Cancer with Bone Metastases

12 December 2012

Algeta to Present at Upcoming Investor Conferences

03 December 2012

Algeta and Ablynx enter into a research collaboration to evaluate the potential of novel alpha-pharmaceuticals comprising thorium-227 conjugated to tumor-targeting Nanobodies®

21 November 2012

Algeta's Financial Calendar 2013

19 November 2012

Algeta results for the third quarter 2012

15 November 2012

Algeta to Participate in Upcoming Investor Conferences

07 November 2012

Algeta schedules third quarter 2012 results presentation, webcast and conference call

05 November 2012

Algeta: New analyses from phase III ALSYMPCA trial in patients with castration-resistant prostate cancer with bone metastases presented at ESMO 2012

01 October 2012

Algeta US Celebrates Official Opening of Operational Center in Cambridge, MA, USA

18 September 2012

Algeta: New analyses from phase III ALSYMPCA trial in patients with castration-resistant prostate cancer to be presented at ESMO 2012

17 September 2012

Algeta to Participate in Upcoming Investor Conferences

03 September 2012

Algeta results for the first half and second quarter 2012

16 August 2012

Algeta initiates new R&D program to investigate a Targeted Thorium Conjugate (TTC) against hematological cancers

16 August 2012

Algeta schedules first half and second quarter 2012 results presentation, webcast and conference call

06 August 2012

Updated phase III data confirm overall survival benefit of Alpharadin in men with advanced prostate cancer that has spread to the bone

04 June 2012

Updated survival results from phase III trial of Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) to be presented as Late-Breaking Abstract at ASCO 2012

16 May 2012

Algeta to Present at Forthcoming Life Sciences Investor Conferences

14 May 2012

CORRECTION: Algeta reports results for the first quarter 2012

03 May 2012

Algeta reports results for the first quarter 2012

03 May 2012

Algeta and Sanofi extend research collaboration evaluating thorium-conjugated tumor-targeting antibody

30 April 2012

Algeta schedules first quarter 2012 results presentation, webcast and conference call

23 April 2012

Annual General Meeting held in Algeta ASA

19 April 2012

Algeta exercises option to co-promote Alpharadin in the United States

12 April 2012

Algeta ASA - Notice of Annual General Meeting 2012

29 March 2012

Algeta to Present at Forthcoming Life Sciences Investor Conferences

15 March 2012

Algeta to Present at Forthcoming Life Sciences Investor Conferences

22 February 2012

2011 Annual Report for Algeta ASA

13 February 2012

Analysis of updated ALSYMPCA phase III data confirms overall survival benefit of Alpharadin in castration-resistant prostate cancer patients with bone metastases

10 February 2012

Algeta results for the fourth quarter 2011 and full year 2011

09 February 2012

Expanded Access Program for investigational drug Alpharadin (radium-223 chloride) initiated in the United States

02 February 2012

Algeta schedules fourth quarter 2011 results presentation, webcast and conference call

01 February 2012

Detailed results from ALSYMPCA phase III study highlight the positive impact of Alpharadin on skeletal-related events associated with bone metastases from castration-resistant prostate cancer

01 February 2012

Detailed results from ALSYMPCA phase III study with Alpharadin to be presented at 2012 Genitourinary Cancers Symposium (Abstracts #8 and #9)

27 January 2012

Jeffrey W. Albers appointed President of Algeta US

17 January 2012

Algeta President & CEO Andrew Kay to present at the 30th Annual J.P. Morgan Healthcare Conference

05 January 2012

Positive phase IIa bone marker data of Alpharadin in breast cancer patients with bone metastases presented at 2011 San Antonio Breast Cancer Symposium

09 December 2011

Positive phase IIa bone marker data of Alpharadin in breast cancer patients with bone metastases to be presented at 2011 San Antonio Breast Cancer Symposium

06 December 2011

Algeta results for the third quarter 2011

10 November 2011

Algeta's Financial Calendar 2012

07 November 2011

Algeta schedules third quarter 2011 results presentation, webcast and conference call

31 October 2011

Leading Experts in Prostate Cancer Treatment to Present at Algeta R&D Days

18 October 2011

Algeta to Host Investor Meeting, Webcast and Conference Call to Discuss Positive Phase III Trial Results for Alpharadin

26 September 2011

Alpharadin Significantly Improves Overall Survival for Patients with Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases

24 September 2011

Algeta to Present at Forthcoming Life Sciences Investor Conferences

14 September 2011

Alpharadin Phase III Trial Data to be presented at Best and Late-Breaking Session at the 2011 European Multidisciplinary Cancer Congress

13 September 2011

Algeta appoints Mike Booth as Senior Vice President, Communications and Corporate Affairs

08 September 2011

FDA Grants Fast Track Designation to Alpharadin for the Treatment of Castration-Resistant Prostate Cancer Patients with Bone Metastases

23 August 2011

Algeta results for the first half and second quarter 2011

11 August 2011

Algeta schedules second quarter 2011 results presentation, webcast and conference call

01 August 2011

Algeta awarded grant to develop new tumor-targeted alpha-pharmaceuticals based on Thorium

22 June 2011

Algeta announces positive preliminary bone marker results in a phase IIa study evaluating Alpharadin in breast cancer patients with bone metastases

07 June 2011

Gjennombrudd for Algeta

06 June 2011

Positive Outcome of Interim Analysis of pivotal Alpharadin study: Primary endpoint met in Phase III ALSYMPCA study

06 June 2011

Clinical analysis of Alpharadin to be presented at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)

01 June 2011

Algeta Results for the First Quarter 2011

12 May 2011

Algeta Signs Exclusive Worldwide License with Affibody for Two Proprietary Molecules for use in New Tumor-targeted Alpha-pharmaceuticals based on Thorium

05 May 2011

Algeta schedules first quarter 2011 results presentation, webcast and conference call

04 May 2011

Algeta appoints Dr. Donald Coppen as Business Development Director

03 May 2011

ANNUAL GENERAL MEETING HELD IN ALGETA ASA

14 April 2011

SUPPLEMENTARY PROPOSAL FROM THE NOMINATION COMMITTEE OF ALGETA ASA REGARDING REMUNERATION OF THE BOARD OF DIRECTORS

13 April 2011

PROPOSALS FROM THE NOMINATIONS COMMITTEE

12 April 2011

Algeta enters research collaboration to evaluate thorium conjugated with a novel tumor-targeting antibody from Genzyme

04 April 2011

New preclinical study with Alpharadin in breast cancer models to be presented at 2011 American Association for Cancer Research

01 April 2011

Algeta ASA - Notice of Annual General Meeting 2011

22 March 2011

New analysis with Alpharadin to be presented at 2011 Genitourinary Cancers Symposium

16 February 2011

Algeta results for the 4th quarter and Full Year 2010

10 February 2011

Algeta schedules fourth quarter 2010 results presentation, webcast and conference call

03 February 2011

Algeta President & CEO Andrew Kay to present at the 29th annual JPMorgan Healthcare conference

05 January 2011

Algeta completes enrolment of 900 patients into phase III ALSYMPCA trial with Alpharadin

05 January 2011

Algeta to present at forthcoming life sciences investor conferences

29 November 2010

Algeta results for the third quarter 2010

12 November 2010

Algeta appoints Lars Abrahmsén as Senior Vice President, Protein Therapeutics

10 November 2010

Algeta schedules third quarter 2010 results presentation, webcast and conference call

03 November 2010

Alpharadin found to be safe and easy to use in patients with bone metastases resulting from castration-resistant prostate cancer (CRPC)

03 November 2010

Algeta to present on the preparation and use of Alpharadin in a clinical setting at the 52nd ASTRO annual meeting

01 November 2010

Algeta signs exclusive agreement with Lumiphore, Inc. to access proprietary technology to enhance its Thorium platform

21 October 2010

Algeta and Bayer to present analysis from Alpharadin clinical program at 35th ESMO Congress

08 October 2010

Algeta to present at forthcoming life sciences investor conferences

14 September 2010

Algeta's financial calendar 2011

06 September 2010

Algeta results for the second quarter and first half 2010

13 August 2010

Algeta announces first cancer patient treated in phase I/IIa trial of Alpharadin in combination with docetaxel chemotherapy

11 August 2010

Algeta schedules second quarter 2010 results presentation and webcast

09 August 2010

Algeta concludes agreements for the manufacture and supply of Alpharadin for future commercial sale.

22 July 2010

Algeta to present at two upcoming life sciences

07 June 2010

Clinical analyses from Alpharadin clinical program to be presented at ASCO

04 June 2010

Algeta hosts Capital Markets Day in Oslo

25 May 2010

Algeta Results for the First Quarter 2010

07 May 2010

Algeta schedules First Quarter 2010 Presentation

03 May 2010

Algeta completes successful sample size re-estimation of pivotal ALSYMPCA trial

03 May 2010

Leading medical experts in bone metastases and prostate cancer therapy to present at Algeta Capital Markets Days

26 April 2010

Algeta elects US experienced pharma industry executives Judith Hemberger and Kapil Dhingra to its Board of Directors

26 April 2010

Annual general meeting held in Algeta

22 April 2010

Algeta voted innovator of the year in Norway

16 April 2010

PROPOSAL FROM THE NOMINATION COMMITTEE OF ALGETA ASA REGARDING REMUNERATION OF THE BOARD OF DIRECTORS IN 2010

13 April 2010

Algeta ASA - Notice of Annual General Meeting 2010

07 April 2010

New clinical analyses from Alpharadin clinical programs to be presented at 2010 Genitourinary Cancers Symposium

05 March 2010

Algeta to present at Cowen's 30th Annual Health Care Conference

04 March 2010

Save the Dates: Algeta to host Capital Markets Days in Oslo (25 May) and London (27 May)

01 March 2010

Algeta Results for the Fourth Quarter and Full Year 2009

19 February 2010

Algeta schedules Fourth Quarter 2009 Presentation

12 February 2010

Algeta announces first patient treated in phase II trial of Alpharadin to treat bone metastases in breast cancer

01 February 2010

Algeta's financial calendar 2010

25 January 2010

Algeta and IFE agree to collaborate for the manufacture and supply of Alpharadin for future commercial use and clinical trials

18 January 2010

Algeta to present at 28th Annual J.P. Morgan Healthcare Conference

06 January 2010

Algeta announces first US patient randomized in ALSYMPCA phase III study at Tulane Cancer Center, New Orleans

11 December 2009

Algeta Results for the Third Quarter 2009

13 November 2009

Algeta schedules Third Quarter 2009 Presentation

04 November 2009

New phase II data presented at ECCO 15 - 34th ESMO Congress reinforces exciting potential of Algeta's Alpharadin as a new treatment for bone metastases in cancer patients

22 September 2009

Algeta to present new clinical data from three phase II trials with Alpharadin at ECCO 15 - 34th ESMO Congress

17 September 2009

Algeta signs $800 million (EUR 560m) global agreement with Bayer for development and commercialization of Alpharadin for bone metastases

03 September 2009

Algeta Results for the Second Quarter and for First Half of 2009

14 August 2009

Algeta appoints Dr. Gillies O'Bryan-Tear as Chief Medical Officer

24 July 2009

Algeta schedules Second Quarter 2009 Presentation

23 July 2009

Algeta to present at Piper Jaffray Fourth Annual Europe Conference in London

19 June 2009

New research highlights potential of novel alpha-pharmaceutical in targeting and killing breast cancer cells

17 June 2009

Algeta demonstrates potential of alpha-emitter platform to generate new antibody therapeutics targeting breast cancer and lymphoma

09 June 2009

Algeta to present at BioEquity Europe 2009

03 June 2009

Annual General Meeting held in Algeta

15 May 2009

Algeta Reports Results for the First Quarter 2009

15 May 2009

Algeta ASA - extends deadline for AGM attendance and proxies to 13 May 16:00

11 May 2009

Algeta schedules First Quarter 2009 Presentation and Conference Call

06 May 2009

Algeta ASA - Notice of Annual General Meeting 2009

30 April 2009

Algeta ASA - Annual report 2008

29 April 2009

Increase share capital

08 April 2009

Algeta provides update on major shareholdings following its recent fundraising

17 March 2009

Extraordinary General Meeting held in Algeta ASA

04 March 2009

Algeta ASA announces name candidate proposed for election to the Board at the EGM on 4 March 2009

02 March 2009

Algeta Reports Results for the Fourth Quarter 2008

27 February 2009

Algeta schedules Fourth Quarter 2008 Presentation and Conference Call

25 February 2009

Algeta calls extraordinary general meeting on 4 March 2009

18 February 2009

Algeta raises USD 35 million (NOK 245 million) in a Private Placement

18 February 2009

Private Placement

17 February 2009

Algeta to enroll US patients into global phase III ALSYMPCA trial following successful end-of-phase II meeting with FDA

03 February 2009

Algeta completes comprehensive phase II clinical program with Alpharadin for treating bone metastases in patients with advanced prostate cancer

14 January 2009

Algeta's financial calendar 2009

16 December 2008

Algeta appoints Andrew Kay as President and Chief Executive Officer

11 December 2008

Algeta to Present at Lazard Capital Markets Fifth Annual Healthcare Conference

13 November 2008

Algeta Reports Results for the Third Quarter 2008

05 November 2008

Algeta schedules Third Quarter 2008 Presentation and Conference Call

03 November 2008

Change of financial calendar in Algeta

19 September 2008

Extraordinary General Meeting held in Algeta

16 September 2008

Algeta ASA - Notice of Extra Ordinary General Meeting

28 August 2008

Algeta Reports Positive Headline Phase II Data on Pain Palliation with Alpharadin

28 August 2008

Algeta Reports Results for the Second Quarter and First Half Year 2008

13 August 2008

Algeta begins first US clinical trial of Alpharadin in men with advanced prostate cancer

12 August 2008

Algeta schedules Second Quarter 2008 Presentation and Conference Call

11 August 2008

Positive Biodistribution and Dosimetry Data for Alpharadin Cancer Therapy Presented at the Annual Meeting of the Society for Nuclear Medicine

19 June 2008

Algeta Begins Phase III Clinical Study of Alpharadin in Men with Advanced Prostate Cancer

18 June 2008

Algeta appoints Øystein Soug as Chief Financial Officer

16 May 2008

Annual General Meeting held in Algeta

15 May 2008

Algeta Reports Results for the First Quarter 2008

15 May 2008

Algeta schedules First Quarter 2008 Presentation and Conference Call

13 May 2008

Algeta ASA - Annual Report 2007

23 April 2008

Algeta ASA - Notice of Ordinary General Meeting 2008

23 April 2008

New Preclinical Data on Algeta's Investigational Radiopharmaceutical, Alpharadin(TM), to Be Presented at AACR Annual Meeting

11 April 2008

Annual Financial Statements 2007

31 March 2008

Algeta to participate at the Norwegian Healthcare Seminar for Financial Analysts; "Helseseminar med fokus på kreft"

27 March 2008

Algeta appoints Mr Hellek Bråthen as interim Chief Financial Officer

12 March 2008

Algeta Reports Results for the Fourth Quarter and Full Year 2007

29 February 2008

Algeta receives IND approval for Alpharadin(TM) to commence clinical development in the USA

21 February 2008

Algeta schedules Fourth Quarter and Full Year 2007 Presentation and Conference Call

15 February 2008

Algeta's financial calendar 2008

22 January 2008

Algeta provides update on its late-stage clinical programme for Alpharadin in prostate cancer

20 December 2007

Extra Ordinary General Meeting held in Algeta

06 December 2007

Algeta ASA - Notice of Extra Ordinary General Meeting 2007

20 November 2007

Algeta Reports Results for Third Quarter 2007

09 November 2007

Algeta schedules Third Quarter 2007 presentation and conference call

29 October 2007

Algeta presents at leading nuclear medicine conference

15 October 2007

KORR* Algeta to present at leading international investor conferences

01 October 2007

Algeta to present at leading international investor conferences

01 October 2007

Forlenger livet med Alpharadin

25 September 2007

Alpharadin treatment more than doubles survival rate in prostate cancer patients

25 September 2007

Algeta to appoint new Chief Financial Officer

17 September 2007

Algeta Appoints Dr. Peter Harris as Chief Medical Officer

14 September 2007

Algeta Reports Results for Second Quarter 2007

10 August 2007

Algeta presenterer rapport for 2. kvartal 2007

10 August 2007

Algeta schedules Second Quarter 2007 presentation and conference call

01 August 2007

Algeta inviterer til presentasjon og telefonkonferanse Resultater for 2. kvartal 2007

01 August 2007

Algeta Expands its TH-1 Targeted Cancer Therapy Program

02 July 2007

Algeta utvider forskningsprogram for kreftbehandling

02 July 2007

Algeta Begins Clinical Dosimetry Study with Alpharadin(TM) Prostate Cancer Patients

29 June 2007

Algeta starter studie med Alpharadin i prostatakreft-pasienter

29 June 2007

Algeta extends research agreement with the Norwegian Radium Hospital

18 June 2007

Algeta forlenger forskningsavtale med Radiumhospitalet

18 June 2007

Algeta demonstrates targeted cancer-killing potential of novel alpha particle linked antibodies in leading medical journal Blood

14 June 2007

Algetas teknologi basert på målsøkende molekyler presenteres i det ledende medisinske tidsskriftet Blood

14 June 2007

Algeta's Phase II Clinical Study Data for Alpharadin(TM) in Prostate Cancer Published in Lancet Oncology

04 June 2007

Algetas resultater for pasienter med prostatakreft publisert i Lancet Oncology

04 June 2007

Algeta to Present Phase II Clinical Study Data for Alpharadin(TM) in Prostate Cancer at ASCO

30 May 2007

Algeta presenterer kliniske studier i USA

30 May 2007

Algeta presenterer på prestisjetung investorkonferanse

16 May 2007

Algeta to Present at BioEquity Europe 2007 Conference

16 May 2007

Exercise and Allotment of Employee Share Options in Algeta ASA

15 May 2007

Exercise and Allotment of Employee Share Options in Algeta ASA

15 May 2007

Første kvartal et vendepunkt for Algeta

11 May 2007

Algeta Reports Results for First Quarter 2007 - A period of significant achievement for Algeta

11 May 2007

Ordinær Generalforsamling avholdt i Algeta

11 May 2007

Ordinary General Meeting held in Algeta

11 May 2007

Algeta inviterer til presentasjon og telefonkonferanse - Resultater for 1. kvartal 2007

04 May 2007

Algeta schedules First Quarter 2007 presentation and conference call

04 May 2007

Algeta Presents Technology and Clinical Data at 17th International Symposium on Radiopharmaceutical Sciences

27 April 2007

Algetas unike teknlogi presenteres på prestisjefylt symposium

27 April 2007

Algeta ASA - Annual Report 2006

26 April 2007

Algeta ASA - Årsrapport 2006

26 April 2007

Innkalling til ordinær generalforsamling 2007 i Algeta ASA

26 April 2007

Algeta ASA - Notice of Annual General Meeting 2007

26 April 2007

Algeta Appoints Roger Harrison as Chief Business Officer

23 April 2007

Algeta utnevner internasjonal tungvekter som Chief Business Officer

23 April 2007

Algeta listed on the Oslo Stock Exchange

27 March 2007

Algeta notert på Oslo Børs

27 March 2007

Algeta henter 250 millioner i vellykket emisjon

26 March 2007

Algeta raises NOK 250 million in successful offering

26 March 2007

Algeta prospectus approved by Oslo Stock Exchange

09 March 2007

Algetas prospekt godkjent av Oslo Børs

09 March 2007

Algeta - Initial Public Offering

08 March 2007

Algeta - Initial Public Offering

08 March 2007

Norske Algeta øker overlevelsen for pasienter med prostatakreft

26 February 2007

Algeta's Alpharadin(TM) significantly improves patient survival in a clinical trial in prostate cancer

26 February 2007

Algeta søker om notering på Oslo Børs

01 February 2007

Algeta applies for listing on the Oslo Stock Exchange

01 February 2007

Algeta's Alpharadin(TM) reduces PSA levels significantly in a placebo-controlled trial in prostate cancer patients

23 October 2006

Algeta's Alpharadin(TM) reduces PSA levels significantly in a placebo-controlled trial in prostate cancer patients

23 October 2006

Algeta appoints Chief Medical Officer and Chief Scientific Officer

10 August 2006

Algeta appoints Chief Medical Officer and Chief Scientific Officer

10 August 2006

Algeta demonstrates radioimmunotherapeutic potential of a tumor-targeting monoclonal antibody labeled with the alpha-emitting nuclide Thorium-227

23 March 2006

Algeta demonstrates radioimmunotherapeutic potential of a tumor-targeting monoclonal antibody labeled with the alpha-emitting nuclide Thorium-227

23 March 2006

Algeta's Phase II clinical study of Alpharadin(TM) highlights its potential as a treatment for bone metastases in prostate cancer patients - meets primary endpoint in bone marker analysis

27 February 2006

Algeta ASA - Interim data from Phase II clinical study of Alpharadin as a treatment for bone metastases in prostate cancer patients to be presented at 2006 Prostate Cancer Symposium

10 February 2006

Algeta utvider klinisk fase 2 studie med Alpharadin(TM) for pasienter med prostatakreft til England

27 August 2004

Algeta Extends Alpharadin(TM) Phase II Trial For Prostate Cancer to UK

27 August 2004

Algeta Broadens Technology Base with Radioactive Liposomes

14 May 2004